Short Interest in Mustang Bio, Inc. (NASDAQ:MBIO) Drops By 22.4%

Mustang Bio, Inc. (NASDAQ:MBIO) saw a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 91,700 shares, a drop of 22.4% from the February 13th total of 118,200 shares. Based on an average daily volume of 310,600 shares, the short-interest ratio is currently 0.3 days. Currently, 6.4% of the shares of the stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Mustang Bio stock. Geode Capital Management LLC boosted its holdings in Mustang Bio, Inc. (NASDAQ:MBIO) by 15.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 284,437 shares of the company’s stock after buying an additional 38,951 shares during the quarter. Geode Capital Management LLC owned approximately 29.63% of Mustang Bio worth $50,000 at the end of the most recent reporting period. 9.95% of the stock is currently owned by hedge funds and other institutional investors.

Mustang Bio Stock Performance

Shares of NASDAQ MBIO traded down $0.01 during mid-day trading on Monday, reaching $1.41. The company had a trading volume of 21,427 shares, compared to its average volume of 243,380. Mustang Bio has a one year low of $1.35 and a one year high of $67.00. The firm has a market cap of $1.34 million, a price-to-earnings ratio of -0.02 and a beta of 1.82. The business’s 50-day simple moving average is $4.23 and its 200 day simple moving average is $8.89.

Mustang Bio Company Profile

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.